KalVista Pharmaceuticals, Inc. Stock News

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing approval for EKTERLY® (sebetralstat), a novel plasma kallikrein inhibitor, for the treatment of acute attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 ...

KalVista Pharmaceuticals, Inc. ( KALV ) Jefferies London Healthcare Conference 2025 November 19, 2025 8:30 AM EST Company Participants Benjamin Palleiko - CEO & Director Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Presentation Maurice Raycroft Jefferies LLC, Research Division Hi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jef...

KalVista Pharmaceuticals, Inc. ( KALV ) Q3 2025 Earnings Call November 11, 2025 8:30 AM EST Company Participants Ryan Baker - Head of Investor Relations Benjamin Palleiko - CEO & Director Paul Audhya - Chief Medical Officer Nicole Sweeny - Chief Commercial Officer Brian Piekos - Chief Financial Officer Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Stacy Ku - T...

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided an operational update and reported financial results for the third quarter ended September 30, 2025. “The US launch of EKTERLY is progressing with significant momentum, driven by strong early demand and rapid adoption among physicians and people living with HAE. We continue to ...

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new patient satisfaction and pediatrics data from its clinical studies of EKTERLY® (sebetralstat), the first and only oral on-demand treatment for hereditary angioedema (HAE), as well as physician and patient survey and consensus study data highlighting the substantial unmet ne...

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at each of the following upcoming investor conferences: Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025, at 8:40 a.m. EST Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025, at...

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) will host a conference call and webcast on Tuesday, November 11, 2025, at 8:30 a.m. ET to review the Company's third quarter financial results and provide an operational update. The live audio webcast will be accessible on the Investors section of the Company's website at www.ir.kalvista.com/e...

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of one abstract for late-breaking oral presentation and three for poster presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting taking place in Orlando, Florida from November 6–10, 2025. The lake-breaking oral ...